Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2017-05-10 Earnings Release
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'GeNeuro : trésorerie et revenus du 1er trimestre 2017'. It provides a summary of financial highlights (revenue and cash position) for the first quarter of 2017. It is not a full quarterly report (IR) but rather an initial announcement of these specific financial metrics, which fits the definition of an Earnings Release (ER). Q1 2017
2017-05-10 French
Quarterly financial report / First quarter financial report
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro reporting its cash position and operating revenues for the first quarter of 2017. It provides key financial highlights rather than a full comprehensive financial report. According to the filing definitions, an initial announcement of quarterly financial results (key highlights only) is classified as an Earnings Release (ER). Q1 2017
2017-05-10 English
Document availability communications / Methods of making financial reports or updated prospectuses available
Report Publication Announcement Classification · 1% confidence The document is a short press release (1891 characters) announcing the publication and availability of the company's 2016 Reference Document. It explicitly states that the document has been filed with the AMF and provides a link to the company website for viewing/downloading. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, making it a Report Publication Announcement (RPA).
2017-05-02 English
Communiqués de mise à disposition de documents / Modalités de mise à disposition document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that GeNeuro has made its 2016 reference document (document de référence) available to the public. It provides instructions on where to access the report and lists the contents included within that report. Per the 'Menu vs Meal' rule, since this is a short announcement regarding the publication of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2017-04-28 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release issued by GeNeuro announcing the initiation of a Phase 2a clinical study for their drug candidate GNbAC1 in Type 1 Diabetes. It details the study design, the rationale behind the research, and provides contact information. Since this is a general corporate announcement regarding clinical trial progress and does not fit into specific financial reporting categories like 10-K, IR, or ER, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2017-04-18 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the launch of a Phase IIa clinical trial for their drug candidate GNbAC1 in patients with type 1 diabetes. It details the study design, the scientific rationale, and provides background information on the company and the disease. This type of corporate announcement regarding clinical trial milestones and operational updates is classified as a Regulatory Filing (RNS) in the absence of a more specific category like 'Clinical Trial Results' or 'Product Pipeline Update'.
2017-04-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.